PT3925952T - Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata - Google Patents
Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstataInfo
- Publication number
- PT3925952T PT3925952T PT211776430T PT21177643T PT3925952T PT 3925952 T PT3925952 T PT 3925952T PT 211776430 T PT211776430 T PT 211776430T PT 21177643 T PT21177643 T PT 21177643T PT 3925952 T PT3925952 T PT 3925952T
- Authority
- PT
- Portugal
- Prior art keywords
- prostate
- endo
- radiotherapy
- specific membrane
- membrane antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3925952T true PT3925952T (pt) | 2023-12-13 |
Family
ID=59899817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT211776430T PT3925952T (pt) | 2016-03-22 | 2017-03-22 | Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata |
| PT177710282T PT3433238T (pt) | 2016-03-22 | 2017-03-22 | Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177710282T PT3433238T (pt) | 2016-03-22 | 2017-03-22 | Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (pt) |
| EP (3) | EP4385981A1 (pt) |
| JP (3) | JP7073270B2 (pt) |
| KR (4) | KR20250057132A (pt) |
| CN (3) | CN120172884A (pt) |
| AU (1) | AU2017238181B2 (pt) |
| BR (1) | BR112018069507A2 (pt) |
| CA (1) | CA3018709A1 (pt) |
| CL (1) | CL2018002683A1 (pt) |
| CY (1) | CY1124487T1 (pt) |
| DK (2) | DK3433238T3 (pt) |
| ES (2) | ES2972148T3 (pt) |
| FI (1) | FI3925952T3 (pt) |
| HR (2) | HRP20240215T1 (pt) |
| HU (2) | HUE055607T2 (pt) |
| LT (2) | LT3925952T (pt) |
| MX (1) | MX384823B (pt) |
| PH (1) | PH12018502048A1 (pt) |
| PL (2) | PL3433238T3 (pt) |
| PT (2) | PT3925952T (pt) |
| RS (2) | RS65188B1 (pt) |
| RU (2) | RU2021115958A (pt) |
| SA (1) | SA518400103B1 (pt) |
| SI (2) | SI3433238T1 (pt) |
| TR (1) | TR201813644T1 (pt) |
| WO (1) | WO2017165473A1 (pt) |
| ZA (1) | ZA201806389B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017311510B2 (en) | 2016-08-10 | 2021-11-18 | Cancer Targeted Technology Llc | Chelated PSMA inhibitors |
| JP7167021B2 (ja) * | 2016-11-23 | 2022-11-08 | キャンサー ターゲテッド テクノロジー エルエルシー | アルブミン結合ｐｓｍａ阻害剤 |
| ES2972577T3 (es) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP) |
| US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
| ES2997266T3 (en) * | 2017-12-11 | 2025-02-14 | Univ Muenchen Tech | Psma ligands for imaging and endoradiotherapy |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| US10377778B2 (en) * | 2017-12-13 | 2019-08-13 | Sciencons AS | Lead and thorium compounds |
| CN118146196A (zh) * | 2018-02-06 | 2024-06-07 | 海德堡大学 | Fap抑制剂 |
| MX2020008247A (es) | 2018-02-06 | 2021-02-26 | Univ Johns Hopkins | Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer. |
| SG11202009649RA (en) * | 2018-03-30 | 2020-10-29 | Futurechem Co Ltd | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
| US12128115B2 (en) | 2018-04-27 | 2024-10-29 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| BR112021005931A2 (pt) * | 2018-09-28 | 2021-06-29 | Universität Heidelberg | composto, complexo e composição farmacêutica |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| MX2022000136A (es) * | 2019-07-02 | 2022-04-27 | Advanced Accelerator Applications Italy Srl | Ligandos del antigeno de membrana especifico de la prostata (psma) y usos de los mismos. |
| US20220273826A1 (en) * | 2019-07-02 | 2022-09-01 | Novartis Ag | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| KR20230002829A (ko) | 2020-04-29 | 2023-01-05 | 노파르티스 아게 | Psma 결합 리간드의 방사성 표지 방법 및 이의 키트 |
| EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230406847A1 (en) | 2020-11-12 | 2023-12-21 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| EP4247798B1 (en) * | 2020-11-19 | 2025-08-27 | Novartis AG | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| AU2022293573A1 (en) * | 2021-06-17 | 2023-12-14 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| CN118647415A (zh) | 2022-02-09 | 2024-09-13 | 诺华股份有限公司 | 包含225锕标记的络合物和铋多价螯合剂的药物组合物 |
| KR20250127126A (ko) * | 2022-12-21 | 2025-08-26 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료 |
| AU2024298619A1 (en) | 2023-07-21 | 2026-01-29 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5680409B2 (ja) | 2007-06-26 | 2015-03-04 | ザ ジョンズ ホプキンス ユニバーシティ | 前立腺特異膜抗原（ｐｓｍａ）の標識阻害剤、生物学的評価およびイメージング剤としての使用 |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| TW201034689A (en) * | 2008-12-05 | 2010-10-01 | Molecular Insight Pharm Inc | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
| EP3222617B1 (en) | 2009-03-19 | 2022-07-06 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| ES2732060T3 (es) * | 2011-08-05 | 2019-11-20 | Molecular Insight Pharm Inc | Inhibidores radiomarcados del antígeno de membrana específico de la próstata |
| CN107382890B (zh) * | 2011-11-30 | 2021-01-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| AU2014205304B2 (en) * | 2013-01-14 | 2018-03-29 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| SI4095130T1 (sl) * | 2013-10-18 | 2024-05-31 | Novartis Ag | Označeni zaviralci za prostato specifičnega membranskega antigena (PSMA), njihova uporaba kot kontrastna sredstva in farmacevtska sredstva za zdravljenje raka prostate |
| JP6749249B2 (ja) * | 2014-05-06 | 2020-09-02 | ザ ジョンズ ホプキンズ ユニヴァーシティー | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 |
| WO2016030329A1 (en) * | 2014-08-24 | 2016-03-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| US11420910B2 (en) * | 2014-10-30 | 2022-08-23 | Katholieke Universitet Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 BR BR112018069507-6A patent/BR112018069507A2/pt active Search and Examination
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3925952T (pt) | Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata | |
| EP3630733A4 (en) | HIGH AFFINITY AGENTS TARGETING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN FOR ENDORADIOTHERAPY IN PROSTATE CANCER | |
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| IL268974B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
| IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
| EP3710039A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH | |
| CL2018000604A1 (es) | Inhibidores marcados con 18f mejorados del antígeno de membrana específica de próstata (psma) y su uso como agentes de formación de imágenes para cáncer de próstata. | |
| PT3458052T (pt) | Tratamento combinado do cancro | |
| IL265697B1 (en) | Treatment of prostate cancer | |
| MA45780A (fr) | Méthodes de traitement du cancer de la prostate | |
| IL277695B1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| MA44612A (fr) | Méthodes de traitement de cancers pédiatriques | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| EP3983016A4 (en) | METHODS OF TREATMENT OF CANCER BY TARGETING COLD TUMORS | |
| EP3568694A4 (en) | DOXORUBICIN-GOLD NANOCONJUGATES TARGETED FOR ANTITUMOR THERAPY | |
| IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
| EP3496736A4 (en) | Tlr9 targeted therapeutics | |
| EP3717003A4 (en) | CANCER THERAPY BASED ON NANOPARTICLES | |
| EP3706752A4 (en) | COMBINATORY THERAPY FOR ANTI-CANCER TREATMENT | |
| HK40028154A (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| HK1259764A1 (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| BR112018002732A2 (pt) | Agente terapêutico para tumor | |
| BR112017005002A2 (pt) | macropinocitose de anticorpos anti-cd46 humanos e agentes terapêuticos dirigidos contra o câncer. |